RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

After the R/S, the authorized shares will be at 70 mil, and the shares outstanding (incl warrants, options, etc) will be roughly half that, so that gives them plenty of room to raise money via future equity financings. Assuming a .02 cent share price at the time of the R/S, the post-R/S is 6.50/share.

Often with a R/S there is an associated equity financing, which recapitalizes the company and refills the cash coffers. So the elements are coming into place to complete the turnaround of the company - clinical results, reverse split, and recapitalization. The higher share price is also a prerequisite for a future uplisting onto one of the Nasdaq exchanges.

So kudos to management. The overall timing has worked out well, since the CX-1739 RD results will be out this Summer, producing a good vibe for the R/S and recapitalization, and the Dronabinol results will also be forthcoming, probably in the Fall, which will maintain an atmosphere of positive anticipation in the post-R/S period.

Then with the recapitalization, the company can announce future plans for CX-1739 in RD and also a new Ampakine trial in Central Sleep Apnea. They apparently are also planning to bring back CX-717, which will save a lot of development time and allow more clinical indications and trials.